期刊文献+

左卡尼汀对老年冠心病合并充血性心力衰竭患者NT-proBNP和肌钙蛋白水平的影响 被引量:14

Effect of L-carnitine Injection on NT-proBNP and Troponin Levels for Senile Patients with Coronary Heart Disease and Congestive Heart Failure
在线阅读 下载PDF
导出
摘要 目的:探讨左卡尼丁注射液对老年冠心病合并充血性心力衰竭患者血浆N末端前脑钠肽(NT-pro BNP)及肌钙蛋白水平的影响。方法:冠心病合并充血性心力衰竭患者124例,随机均分为对照组与观察组,对照组患者给予常规治疗及安慰剂15 m L/次,2次/d,观察组患者给予常规治疗及左卡尼丁注射液15 m L/次,2次/d,分别测定两组患者治疗前和治疗第14天时血浆NT-pro BNP、肌钙蛋白及左室射血分数(LVEF),记录两组患者治疗第14天的临床疗效。结果:两组患者治疗后NT-pro BNP和肌钙蛋白水平均下降,LVEF升高,且观察组比对照组改善更明显,差异均有统计学意义(P<0.05);观察组患者的临床有效率显著高于对照组,差异有统计学意义(P<0.05)。结论:左卡尼汀注射液可能通过下调NT-pro BNP和肌钙蛋白水平改善老年冠心病合并充血性心力衰竭患者心衰指标,提高临床疗效。 Objective: To investigate the clinical effect of L-carnitine injection on NT-pro BNP and troponin levels for senile patients with coronary heart disease and congestive heart failure. Methods: A total of 124 patients were divided into the control and experiment groups with equal numbers. The patients in control group received the common treatment and placebo of 15 mL per time,twice a day; the patients in experiment group received the common treatment and L-carnitine injection 15 mL per time,twice a day; then to compare the differences of NT-pro BNP and troponin levels,Left ventricular ejection fraction( LVEF),and the clinical effect 14 days later. Results: The NT-pro BNP and troponin levels of both groups were lower,and LVEF was higher than before,those of experiment group were all significantly improved than those of control group,differences were statistically significant( P〈0. 05).Clinical efficacy rate in experiment group was significantly higher( P〈0. 05). Conclusions: L-carnitine injection can improve the clinical effect for senile patients with coronary heart disease and congestive heart failure.
作者 曲鑫 戴珩
出处 《贵阳医学院学报》 CAS 2015年第5期490-492,共3页 Journal of Guiyang Medical College
关键词 左卡尼汀 老年人 冠状动脉疾病 心力衰竭 充血性 肌钙蛋白 N末端前脑钠肽 L-carnitine injection aged coronary diseases heart failure, congestive troponin N terminal pro brain natriuretic peptide
作者简介 通信作者E-mail:quxinshengjing@163.com
  • 相关文献

参考文献7

二级参考文献33

  • 1张义平,韩跃刚,缑东亮.左卡尼汀治疗慢性心力衰竭疗效观察[J].河南职工医学院学报,2006,18(2):101-103. 被引量:6
  • 2殷仁富,陈金明.心脏能量学:代谢与治疗[M].上海:第二军医大学出版社,2002.
  • 3van Bilsen M, Smeets PJ, Gilde AJ, et al. Metabolic remodelling of the failing heart: the cardiac burn out syndrome? [J]. Cardiovasc Res,2004,61 (2) :218-226.
  • 4Tuunanen H, Knuuti J. Metabolic remodelling in human heart failure[J]. Cardiovasc Res,2011,90(2) :251 -257.
  • 5Tuunanen H, Engblom E, Naum A, et al. Free fatty acid depletion acutely decreases cardiac work and efficiency in cardiomyopathic heart failure [J]. Circulation, 2006, 114 (20) :2130-2137.
  • 6Halbirk M, Norrelund H, Moller N, et al. Suppression of circulating free fatty acids with acipimox in chronic heart failure patients changes whole body metabolism but does not affect cardiac function[J]. Am J Physiol Heart Circ Physiol, 2010,299(4) :H1220- 1225.
  • 7Abozguia K, Elliott P, McKenna W, et al. Metabolic modulator perhexiline corrects energy deficiency and improves exercise capacity in symptomatic hypertrophic cardiomyopathy [J]. Circulation,2010,122(16) : 1562- 1569.
  • 8Rupp H, Zarain-Herzberg A, Maisch B. The use of partial fatty acid oxidation inhibitors for metabolic therapy of angina pectoris and heart failure[J]. Herz, 2002,27(7) :621-636.
  • 9Bristow M. Etomoxir: a new approach to treatment of chronic heart failure[J]. Lancet,2000,356(9242) :1621-1622.
  • 10Holubarseh CJ, Rohrbach M, Karrasch M, et al. A double- blind randomized multicentre clinical trial to evaluate the efficacy and safety of two doses of etomoxir in comparison with placebo in patients with moderate congestive heart failure: the ERGO (etomoxir for the recovery of glucose oxidation) study [J]. Clin Sci (Lond), 2007, 113 (4): 205-212.

共引文献59

同被引文献133

  • 1李菲,刘英春,邓文,范觉新.左卡尼丁对老年慢性充血性心衰的心功能及血脂的影响[J].现代预防医学,2012,39(22):6086-6087. 被引量:6
  • 2范毅敏,陈纯,甄宇峰,沈娜君,覃丽君,夏焱.左卡尼汀治疗蒽环类抗肿瘤药物所致心脏毒性的临床观察——附30例报告[J].新医学,2007,38(4):229-231. 被引量:18
  • 3葛均波,徐永健.内科学[M].8版.北京:人民卫生出版社,2014:42,53,50.
  • 4Kwon TG, Bae JH, Jeong MH, et al. N-terminal pro-B- type natriuretic peptide is associated with adverse short- term clinical outcomes in patients with acute ST-elevation myocardial infarction underwent primary percutaneous cor- onary intervention [ J ]. Int J Cardiol, 2009 (2) : 173 - 178.
  • 5Mehta SR, Granger CB, Boden WE, et al. Early versus delayed invasive intervention in acute coronary syndromes [J].N Engl J Med, 2009(21):2165 -2175.
  • 6Regitz V,Shug A L,Fleck E.Defective myocardial car nitine metabolism in congestive heart failure.Secondary to dilated cardiomyopathy and to coronary,hypertensive and valvular heart disease[J].Am J Cardiol,1990,65(11):755-769.
  • 7Spagnolil G,Corsi M,Villaschi S,et al.Myocardial carnitine deficiency in acute myocardial infarction[J].Lancet,1982,1(8286):1419-1458.
  • 8桑小溪,田秋生.72例左卡尼汀治疗冠心病心力衰竭临床疗效观察[J].中国保健营养(下旬刊),2014,22(1):397-398.
  • 9Robert Ringseis, Janine Keller, Klaus Eder. Role of carnitine in the regulation of glucose homeostasis and insulin sensitivity : evidence fix>m in vivo and in vitro Studies with carnitine supplementation and carni-tine deficiency[J]. European Journal of Nutrition,2012,51 (1) :1.
  • 10Mojtaba E,Somayeh B,PaymanA,et al. Carnitine,metabolism,supple-mentation and exercise performance[ J]. Indian Journal of Fundamen-tal and Applied Life Sciences,2011,1 (4) :376.

引证文献14

二级引证文献89

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部